Hence, our findings raise the possibility that a significant increase in production of MIP-1α mediated by action of EboGP-pseudotyped HIV VLPs during vaccination may provide an additional mechanism that may potentially drive cell-mediate protection against R5-tropic virus during the initial stage of HIV infection in vivo. This evidence concerns the gene CCL3 and HIV infectious disease.